SIM 0272
Alternative Names: SCR-6277; SCR-6920; SIM-0272Latest Information Update: 28 Jun 2025
At a glance
- Originator Simcere Pharmaceutical Group
- Class Antineoplastics; Small molecules
- Mechanism of Action PRMT5 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Non-Hodgkin's lymphoma; Solid tumours
Most Recent Events
- 28 Jun 2025 No recent reports of development identified for phase-I development in Non-Hodgkin's-lymphoma(Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (PO, Capsule)
- 28 Jun 2025 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (PO, Capsule)
- 20 Oct 2023 Pharmacokinetics and adverse events data from a phase-I trial in Solid tumours presented at the48th European Society for Medical Oncology Congress (ESMO-2023)